ArticleEuropean journal of histochemistry : EJH2025
Maresin 1 alleviates myocardial ischemia-reperfusion injury in rats by suppressing inflammation.
Article in European journal of histochemistry : EJH, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Myocardial ischemia-reperfusion injury (MIRI) induces severe inflammatory damage to cardiac tissue, leading to structural impairment and functional decline. Maresin 1 (MaR1) is an anti-inflammatory lipid mediator derived from macrophages that has shown protective effects in various inflammatory conditions. This study investigated the anti-inflammatory properties and underlying mechanisms of MaR1 in the context of MIRI, both in vivo and in vitro. A rat model of MIRI was established, and MaR1 was administered subcutaneously once daily for one week prior to model induction. Cardiac function was monitored intraoperatively, and serum and myocardial tissue samples were collected postoperatively for analysis. Structural alterations, myocardial injury biomarkers, and inflammatory cytokines were evaluated. In vitro experiments using H9c2 rat cardiomyocytes assessed the effects of MaR1 on cell viability and proliferation. MaR1 treatment significantly improved cardiac function impaired by MIRI, preserved myocardial architecture, and reduced serum and tissue levels of creatine kinase, lactate dehydrogenase, cardiac troponin I, and pro-inflammatory cytokines (IL-1β, IL-6, IL-8, MCP1, and TNF-α). In contrast, MaR1 enhanced the expression of the anti-inflammatory cytokine IL-10. In cultured cardiomyocytes, MaR1 promoted viability and proliferation. Collectively, these findings demonstrate that MaR1 confers protection against MIRI by attenuating inflammation, preserving myocardial structure, improving cardiac function, and enhancing cardiomyocyte survival, underscoring its potential as a therapeutic agent for ischemic cardiac injury.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.